Retatrutide vs Tirzepatide
Tirzepatide is the current standard dual-agonist (GLP-1 + GIP). Retatrutide adds a third receptor — glucagon — for more aggressive metabolic effect in research.
When To Pick Which
More aggressive research targets or plateau on dual-agonist protocols.
Larger research base, well-characterized titration schedule.
Not stacked — both occupy the same receptor space. Choose one.
RESEARCH-GRADE RETATRUTIDE
Source RETATRUTIDE from Blueprint Peak Performance — third-party tested for >99% purity, cold-chain handled, shipped from San Diego. Educational research use only.
Blueprint Research Guide is editorial. The link above sources research-grade compounds from Blueprint Peak Performance — an independent supplier. For educational purposes only. Research use only — not for human consumption, treatment, or diagnosis.
RESEARCH-GRADE TIRZEPATIDE
Source TIRZEPATIDE from Blueprint Peak Performance — third-party tested for >99% purity, cold-chain handled, shipped from San Diego. Educational research use only.
Blueprint Research Guide is editorial. The link above sources research-grade compounds from Blueprint Peak Performance — an independent supplier. For educational purposes only. Research use only — not for human consumption, treatment, or diagnosis.
FAQ
Is Retatrutide stronger than Tirzepatide?
Research suggests larger metabolic effect per dose due to the added glucagon agonism, but side-effect profile scales accordingly.
Can you switch between them?
Researchers typically wash out one before titrating into the other; combining is not standard.
